Comments on: Monday Deal Review: August 17, 2009 http://crossborderbiotech.ca/2009/08/17/monday-deal-review-august-17-2009/ Biotechnology, Health and Business in Canada, the United States and Worldwide Sat, 10 Dec 2011 04:09:15 +0000 hourly 1 http://wordpress.com/ By: Monday Biotech Deal Review: September 14, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/08/17/monday-deal-review-august-17-2009/comment-page-1/#comment-914 Mon, 14 Sep 2009 13:51:30 +0000 http://crossborderbiotech.ca/?p=2920#comment-914 [...] Inc.(TSX: BSY) filed the final prospectus for its $3.1 million rights offering, part of its $4.5 million capital-raising plan.  The prospectus is on SEDAR [...]

]]> By: Monday Deal Review: August 28, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/08/17/monday-deal-review-august-17-2009/comment-page-1/#comment-887 Mon, 31 Aug 2009 17:09:45 +0000 http://crossborderbiotech.ca/?p=2920#comment-887 [...] thermogels for regenerative medicine, made a number of announcements this week, which follow up on previously reported developments. They completed the placement of units for gross proceeds of $1.4 million; they received approval of [...]

]]> By: Another Biotech Windfall from the SIFT Tax: Vasogen Molts for Cervus and Merges with IntelliPharmaCeutics. Shareholders Applaud. « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/08/17/monday-deal-review-august-17-2009/comment-page-1/#comment-845 Tue, 18 Aug 2009 16:40:27 +0000 http://crossborderbiotech.ca/?p=2920#comment-845 [...] at the time that ConjuChem shareholders did not react well to the deal (they still haven’t), we wondered whether future income trusts would find biotech partners willing to try the structure [...]

]]>